Shares of Dyne Therapeutics, Inc. (NYSE:DYN – Get Free Report) have been assigned a consensus recommendation of “Buy” from the five brokerages that are currently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $26.50.
DYN has been the topic of several recent research reports. JPMorgan Chase & Co. increased their target price on Dyne Therapeutics from $20.00 to $22.00 and gave the company an “overweight” rating in a research report on Wednesday. StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, July 16th. Finally, Chardan Capital reissued a “buy” rating and issued a $20.00 price objective on shares of Dyne Therapeutics in a research report on Friday, August 4th.
Check Out Our Latest Report on DYN
Dyne Therapeutics Stock Performance
Dyne Therapeutics (NYSE:DYN – Get Free Report) last announced its quarterly earnings data on Thursday, May 11th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.01). Sell-side analysts predict that Dyne Therapeutics will post -3.4 earnings per share for the current year.
Insider Activity at Dyne Therapeutics
In related news, insider Joshua T. Brumm sold 76,582 shares of Dyne Therapeutics stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $13.34, for a total value of $1,021,603.88. Following the sale, the insider now directly owns 269,771 shares in the company, valued at approximately $3,598,745.14. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider Richard William Scalzo sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $12.03, for a total transaction of $120,300.00. Following the transaction, the insider now directly owns 43,482 shares in the company, valued at approximately $523,088.46. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Joshua T. Brumm sold 76,582 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $13.34, for a total value of $1,021,603.88. Following the transaction, the insider now owns 269,771 shares in the company, valued at $3,598,745.14. The disclosure for this sale can be found here. Insiders sold a total of 275,955 shares of company stock worth $3,529,605 in the last 90 days. Corporate insiders own 32.89% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in DYN. Ameritas Investment Partners Inc. raised its position in shares of Dyne Therapeutics by 49.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,510 shares of the company’s stock valued at $39,000 after buying an additional 1,155 shares during the period. Allspring Global Investments Holdings LLC purchased a new stake in Dyne Therapeutics in the first quarter valued at approximately $51,000. Sphera Funds Management LTD. purchased a new stake in Dyne Therapeutics in the fourth quarter valued at approximately $83,000. Legal & General Group Plc raised its position in Dyne Therapeutics by 59.9% in the second quarter. Legal & General Group Plc now owns 12,757 shares of the company’s stock valued at $88,000 after purchasing an additional 4,779 shares during the period. Finally, UBS Group AG raised its position in Dyne Therapeutics by 2,368.9% in the first quarter. UBS Group AG now owns 10,172 shares of the company’s stock valued at $98,000 after purchasing an additional 9,760 shares during the period. 93.06% of the stock is currently owned by institutional investors and hedge funds.
About Dyne Therapeutics
Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Read More
- Five stocks we like better than Dyne Therapeutics
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- MarketBeat Week in Review – 8/7 – 8/11
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Retailers To Watch Closely Next Week
- What Does Downgrade Mean in Investing?
- Investing in Coffee: 3 Great Strategies to Consider
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
